PASK — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL6422856	0.68	4/20
SCHEMBL6422858	0.68	4/20
SCHEMBL3534816	0.63	4/20
SCHEMBL3525219	0.71	3/20
SCHEMBL7050653	1.00	2/20
SCHEMBL5472468	0.82	2/20
SCHEMBL4763363	0.78	2/20
SCHEMBL5464923	0.77	2/20
SCHEMBL5464927	0.77	2/20
SCHEMBL3584444	0.72	2/20
SCHEMBL309890	1.00	1/20
SCHEMBL1145340	1.00	1/20
SCHEMBL7053671	1.00	1/20
SCHEMBL29391496	1.00	1/20
SCHEMBL31244861	1.00	1/20
SCHEMBL311108	0.96	1/20
SCHEMBL310484	0.95	1/20
SCHEMBL13226237	0.92	1/20
SCHEMBL310393	0.91	1/20
SCHEMBL310380	0.88	1/20

Clinical trials — most relevant to PASK by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Short-Term Metformin Use in Young, Healthy Adults: Impacts on Exercise Capacity	PHASE4	COMPLETED
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus	PHASE3	UNKNOWN
Setmelanotide in Pediatric Participants With Rare Genetic Diseases of Obesity	PHASE3	COMPLETED
Clinical Evaluation of the Effect of Metformin in Sepsis	PHASE3	UNKNOWN
Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome	PHASE3	COMPLETED
Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer	PHASE1/PHASE2	COMPLETED
Sirolimus Treatment in Patients With Autosomal Dominant Polycystic Kidney Disease: Renal Efficacy and Safety	PHASE2	COMPLETED
Everolimus for Children With Recurrent or Progressive Ependymoma	PHASE2	COMPLETED
Phase II Study of Vandetanib in Individuals With Kidney Cancer	PHASE2	COMPLETED
Sorafenib and Interferon Alfa in Treating Patients With Metastatic or Unresectable Kidney Cancer	PHASE2	COMPLETED
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers	PHASE1/PHASE2	NOT_YET_RECRUITING
The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients	PHASE1/PHASE2	WITHDRAWN
A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas	PHASE2	SUSPENDED
Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer	PHASE1	COMPLETED
PAS-004 in Patients With Advanced Solid Tumors	PHASE1	RECRUITING
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors	PHASE1	COMPLETED
Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer	EARLY_PHASE1	COMPLETED
Studying Biomarkers in Tissue Samples From Young Patients With Acute Myeloid Leukemia Previously Enrolled on Clinical Trial POG-9421	nan	COMPLETED
The Effect Of DAAs on miRNA-122 And Insulin Resistance In Chronic HCV Patients	nan	UNKNOWN
Association Between Intakes of Protein, Calcium and Milk With Gene Expression and Linear Growth of School Aged Children	nan	COMPLETED
Dietary Ketosis: Fatty Acids Activate AMPK Energy Circuits Modulating Global Methylation	nan	COMPLETED
Apelin; ACE2 and Biomarkers of Alveolar-capillary Permeability in SARS-cov-2 (COVID-19).	nan	COMPLETED
Parathyroid Hormone (PTH) Homeostasis in Bartter Syndrome	nan	UNKNOWN
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma	nan	COMPLETED
Expression of AMP-activated Protein Kinase (AMPK) Protein in Lung Adenocarcinoma	nan	UNKNOWN
Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies	nan	RECRUITING
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML)	nan	COMPLETED
Intravenous Terbutaline in Severe Status Asthmaticus	nan	UNKNOWN
Evaluation of Vasopressin in the Vessels of Ovarian Neoplasms	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a PASK binder may also engage these)

Protein	Name	Similarity
Q8CEE6	—	0.997	Q8CEE6 →
Q8BLR5	—	0.994	Q8BLR5 →
Q0KK55	—	0.992	Q0KK55 →
Q96PX9	—	0.992	Q96PX9 →
Q9WUL6	—	0.991	Q9WUL6 →
Q0VET5	—	0.991	Q0VET5 →
P0C6A0	—	0.990	P0C6A0 →
Q3UIZ8	—	0.990	Q3UIZ8 →
Q8NDX1	—	0.989	Q8NDX1 →
Q0GGX2	—	0.989	Q0GGX2 →
A0A0A6YY25	—	0.989	A0A0A6YY25 →
Q3U1U7	—	0.989	Q3U1U7 →
Q8K4S1	—	0.989	Q8K4S1 →
Q8BG34	—	0.989	Q8BG34 →
Q6NS69	—	0.989	Q6NS69 →
Q6PAC4	—	0.989	Q6PAC4 →
B1ASB6	—	0.989	B1ASB6 →
Q8BWG4	—	0.988	Q8BWG4 →
Q6DIA7	—	0.988	Q6DIA7 →
Q283Q6	—	0.988	Q283Q6 →
Q76N89	—	0.988	Q76N89 →
Q6P1D7	—	0.988	Q6P1D7 →
Q8BP99	—	0.988	Q8BP99 →
Q8BZW2	—	0.988	Q8BZW2 →
Q76N32	—	0.988	Q76N32 →
Q66H04	—	0.988	Q66H04 →
Q9Z0E3	—	0.988	Q9Z0E3 →
B2RXH4	—	0.988	B2RXH4 →
Q4R736	—	0.988	Q4R736 →
Q5RCQ2	—	0.987	Q5RCQ2 →